Locarnini S - Search Results

1

Update of the statements on biology and clinical impact of occult hepatitis B virus infection.

Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS; Taormina Workshop on Occult HBV Infection Faculty Members. Raimondo G, et al. Among authors: locarnini s. J Hepatol. 2019 Aug;71(2):397-408. doi: 10.1016/j.jhep.2019.03.034. Epub 2019 Apr 18. J Hepatol. 2019. PMID: 31004683 Free article. Review.

2

Statements from the Taormina expert meeting on occult hepatitis B virus infection.

Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Raimondo G, et al. Among authors: locarnini s. J Hepatol. 2008 Oct;49(4):652-7. doi: 10.1016/j.jhep.2008.07.014. Epub 2008 Jul 31. J Hepatol. 2008. PMID: 18715666 No abstract available.

3

Management of treatment failure in chronic hepatitis B.

Zoulim F, Locarnini S. Zoulim F, et al. Among authors: locarnini s. J Hepatol. 2012;56 Suppl 1:S112-22. doi: 10.1016/S0168-8278(12)60012-9. J Hepatol. 2012. PMID: 22300461 Review.

4

Present and future therapies of hepatitis B: From discovery to cure.

Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim F, Chang KM, Lok AS. Liang TJ, et al. Among authors: locarnini s. Hepatology. 2015 Dec;62(6):1893-908. doi: 10.1002/hep.28025. Epub 2015 Oct 27. Hepatology. 2015. PMID: 26239691 Free PMC article. Review.

5

How infectious is the hepatitis B virus? Readings from the occult.

Locarnini S, Raimondo G. Locarnini S, et al. Gut. 2019 Feb;68(2):182-183. doi: 10.1136/gutjnl-2018-316900. Epub 2018 Aug 1. Gut. 2019. PMID: 30068661 No abstract available.

6

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference^‡.

Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Cornberg M, et al. J Hepatol. 2020 Mar;72(3):539-557. doi: 10.1016/j.jhep.2019.11.003. Epub 2019 Nov 12. J Hepatol. 2020. PMID: 31730789 Free article. Review.

7

Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs.

Locarnini S, Hatzakis A, Chen DS, Lok A. Locarnini S, et al. J Hepatol. 2015 Apr;62(1 Suppl):S76-86. doi: 10.1016/j.jhep.2015.01.018. J Hepatol. 2015. PMID: 25920093 Free article. Review.

8

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.

Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C; Hepatitis B Virus Drug Resistance Working Group. Lok AS, et al. Among authors: locarnini s. Hepatology. 2007 Jul;46(1):254-65. doi: 10.1002/hep.21698. Hepatology. 2007. PMID: 17596850 Free article. Review.

9

Hepatitis B virus resistance to nucleos(t)ide analogues.

Zoulim F, Locarnini S. Zoulim F, et al. Among authors: locarnini s. Gastroenterology. 2009 Nov;137(5):1593-608.e1-2. doi: 10.1053/j.gastro.2009.08.063. Epub 2009 Sep 6. Gastroenterology. 2009. PMID: 19737565 Review.

10

Molecular genetics of HBV infection.

Locarnini S, Zoulim F. Locarnini S, et al. Antivir Ther. 2010;15 Suppl 3:3-14. doi: 10.3851/IMP1619. Antivir Ther. 2010. PMID: 21041899 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

390 results

Search Page